Eli Lilly is a drugmaker best known for weight-loss and diabetes blockbusters Zepbound and Mounjaro, plus cancer and Alzheimer's medicines.
Eli Lilly and Company (LLY) is expected to report earnings on Thursday, October 29, 2026, before the open. Estimated release time 07:05 ET. Consensus EPS estimate is $7.54.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $6.40 | $8.38 | — | $22.97B |
| 2026-04-30 | Mar 2026 qtr | $6.97 | $8.27 | +18.7% | $19.80B |
| 2026-02-04 | Dec 2025 qtr | $6.91 | $7.41 | +7.2% | $19.29B |
| 2025-10-30 | Sep 2025 qtr | $5.69 | $7.02 | +23.4% | $17.60B |
| 2025-08-07 | Jun 2025 qtr | $5.60 | $6.30 | +12.5% | $15.56B |
| 2025-05-01 | Mar 2025 qtr | $3.26 | $3.34 | +2.5% | $12.73B |
| 2025-02-06 | Dec 2024 qtr | $5.03 | $5.32 | +5.8% | $13.53B |
| 2024-10-30 | Sep 2024 qtr | $1.47 | $1.18 | — | $11.44B |
LLY has beaten consensus EPS in 6 of its last 6 scored quarters.
LLY pays a quarterly dividend, currently yielding 0.57%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-08-14 | $1.73 | 2026-09-10 |
| 2026-05-15 | $1.73 | 2026-06-10 |
| 2026-02-13 | $1.73 | 2026-03-10 |
| 2025-11-14 | $1.5 | 2025-12-10 |
| 2025-08-15 | $1.5 | 2025-09-10 |
| 2025-05-16 | $1.5 | 2025-06-10 |